Johnson & Johnson said its Janssen Pharmaceutica unit will supply the UK government with its candidate known as Ad26.COV2.S with an initial sale of 30 million doses on a not-for-profit basis for emergency pandemic use. The advance purchase agreement will also provide an option for an additional purchase of up to a 22 million doses, it said. In a separate statement, Novavax said the UK would buy 60 million doses of its coronavirus vaccine candidate, NVX-CoV2373, for a phase 3 clinical trial. The latest agreements bring the UK's total number of doses secured to 362 million for the population of 66 million. J&J said it has also agreed to collaborate with the UK government on a global Phase 3 trial to explore the two-dose regimen of its vaccine candidate.

Source: bd News24 August 14, 2020 06:56 UTC